In addition, such combined consideration of the CD8/FOXP3 ratio and PD-1 and PD-L1 expression to predict patient cluster stratification may guide anti-PD-1/PD-L1 strategies or strategies targeting Treg cells for cancer immunotherapy. This evidence concerns the gene PDCD1 and cancer.